内镜结扎联合中医辨证论治对肝硬化食管静脉曲张破裂出血的二级预防效果

陈冲; 吕莹; 陈茜蕾; 刘成海; 刘平; 慕永平

doi:10.3969/j.issn.1001-5256.2022.05.019

内镜结扎联合中医辨证论治对肝硬化食管静脉曲张破裂出血的二级预防效果

DOI: 10.3969/j.issn.1001-5256.2022.05.019

上海中医药大学附属曙光医院，上海市中医药研究院肝病研究所，肝肾疾病病证教育部重点实验室，上海市中医临床重点实验室，上海 201203

基金项目:

国家自然科学基金 (81874390);

上海市科学技术委员会科技创新项目 (15411950500);

上海市临床重点专科建设项目 (shslczdzk01201)

伦理学声明：本研究方案于2019年3月30日经由上海中医药大学附属曙光医院医学伦理委员会批准，批号：2016-464-15-01。所有患者均签署知情同意书。

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：刘平、慕永平、刘成海负责课题设计，经费支持，指导论文撰写及修订；陈冲负责信息采集，数据分析，论文撰写；吕莹、陈茜蕾负责信息采集。

详细信息

通信作者:
刘平, liuliver@vip.sina.com

慕永平, ypmu8888@126.com

计量
- 文章访问数: 737
- HTML全文浏览量: 174
- PDF下载量: 49
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-27
- 录用日期: 2021-10-29
- 出版日期: 2022-05-20

Effect of endoscopic ligation combined with traditional Chinese medicine syndrome differentiation-based treatment in the secondary prevention of esophageal variceal bleeding in patients with liver cirrhosis

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai Institute of Traditional Chinese Medicine; Key Laboratory of Liver and Kidney Diseases, Ministry of Education; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81874390);

Scientific and Technological Innovation Project of Shanghai Municipal Commission of Science and Technology (15411950500);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)

More Information

Corresponding author: LIU Ping, liuliver@vip.sina.com(ORCID: 0000-0002-6808-8243); MU Yongping, ypmu8888@126.com(ORCID: 0000-0002-6152-4508)

摘要

摘要: 目的观察内镜下结扎联合中医辨证论治防治肝硬化食管静脉曲张破裂出血(EVB)二级预防的疗效。方法选取2015年4月—2021年2月上海中医药大学附属曙光医院肝硬化科收治的行内镜下结扎治疗的EVB患者108例，对同时服用中药治疗的患者定义为中西医组(n=59)，对未服用中药治疗的患者定义西医组(n=49)。比较两组患者的再出血发生率、病死率以及门静脉高压性胃病的改善率等。计量资料符合正态分布者采用t检验；不符合正态分布者采用Mann-Whitney U秩和检验；计数资料2组间对比采用χ²检验或Fisher确切概率法；并采用Cox回归分析评估影响再出血的危险因素。结果中西医组内镜结扎后13~24个月的再出血率显著低于西医组(2% vs 12%, P=0.045)；中西医组再出血病死率显著低于西医组(2% vs 12%, P=0.045)，且门静脉高压性胃病的总有效率显著高于西医组(90% vs 77%, P=0.04)。基础疾病(主要包括糖尿病、高血压、心脏病)及肝功能Child-Pugh分级是影响再出血的显著危险因素(P值均＜0.05)。结论内镜结扎联合中医辨证论治可显著降低EVB的迟发性再出血发生率和病死率，改善门静脉高压性胃病的程度，为结扎联合中医药提高EVB二级预防的综合疗效提供了新策略。
- 肝硬化 /
- 食管和胃静脉曲张 /
- 内窥镜检查 /
- 医学, 中国传统
Abstract: Objective To investigate the efficacy of endoscopic ligation combined with traditional Chinese medicine (TCM) syndrome differentiation-based treatment in the secondary prevention of esophageal variceal bleeding (EVB) in patients with liver cirrhosis. Methods A total of 108 EVB patients who were admitted to Department of Liver Cirrhosis, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from April 2015 to February 2021 and underwent endoscopic ligation were enrolled, among whom 59 patients with TCM treatment were enrolled as Chinese and Western medicine group, and 49 patients without TCM treatment were enrolled as Western medicine group. The two groups were compared in terms of the incidence rate of rebleeding, mortality rate, and the improvement rate of portal hypertensive gastropathy. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups; a Cox regression analysis was used to evaluate the risk factors for rebleeding. Results Compared with the Western medicine group, the Chinese and Western medicine group had a significantly lower rebleeding rate within 13-24 months after ligation (2% vs 12%, P=0.045), a significantly lower mortality rate of rebleeding (2% vs 12%, P=0.045), and a significantly higher overall response rate of portal hypertensive gastropathy (90% vs 77%, P=0.04). Underlying diseases (mainly including diabetes, hypertension, and heart disease) and Child-Pugh class for liver function were significant risk factors for rebleeding (all P < 0.05). Conclusion Ligation combined with TCM treatment can significantly reduce the incidence rate of delayed rebleeding and the mortality rate of EVB and improve the degree of portal hypertensive gastropathy, which provides a new strategy for ligation combined with TCM treatment to improve the overall response of EVB secondary prevention.
- Liver Cirrhosis /
- Esophageal and Gastric Varices /
- Endoscopy /
- Medicine, Chinese Traditional

HTML全文

表 1 两组基线资料比较

Table 1. Comparison of baselines between the two groups

项目	西医组(n=49)	中西医组(n=59)	统计值	P值
性别[例(%)]			χ²=0.02	0.889
男	25(51)	32(54)
女	24(49)	27(46)
年龄(岁)	61.00(50.0~68.0)	57.00(47.0~65.5)	Z=1664.5	0.177
病程(年)	4.00(1.00~8.00)	3.00(1.0~9.0)	Z=1479	0.838
肝硬化原因[例(%)]				0.882
AIH	1(2)	2(3)
PBC	6(12)	6(10)
丙型肝炎肝硬化	1(2)	1(2)
不明原因肝硬化	6(12)	11(19)
混合型肝硬化	6(12)	6(10)
酒精性肝硬化	6(12)	3(5)
血吸虫性肝硬化	3(6)	6(10)
乙型肝炎肝硬化	20(41)	23(39)
重叠综合征(AIH+PBC)	0(0)	1(2)
肝功能指标
TBil(μmol/L)	20.74(11.29~34.50)	20.40(8.80~31.35)	Z=1624.5	0.271
ALT(U/L)	31.00(21.00~39.00)	35.00(22.50~53.50)	Z=1172	0.092
AST(U/L)	38.00(30.00~45.00)	40.00(30.00~56.50)	Z=1248.5	0.224
Alb(g/L)	34.80(30.40~38.41)	35.60(32.15~38.65)	Z=1242.5	0.211
Child-Pugh分级[例(%)]				0.304
A级	18(37)	22(37)
B级	20(41)	30(51)
C级	11(22)	7(12)
食管静脉曲张程度[例(%)]				1.000
中度	5(10)	6(10)
重度	44(90)	53(90)
PHG[例(%)]			χ²=2.935	0.231
无	23(47)	19(32)
轻度	16(33)	28(47)
重度	10(20)	12(20)
高血压病[例(%)]			χ²=0.417	0.518
无	40(82)	44(75)
有	9(18)	15(25)
糖尿病[例(%)]			χ²=0.123	0.725
无	35(71)	45(76)
有	14(29)	14(24)
心脏病[例(%)]				1.000
无	48(98)	57(97)
有	1(2)	2(3)
饮酒史[例(%)]			χ²=0.101	0.750
无	36(73)	46(78)
有	13(27)	13(22)
吸烟史[例(%)]				1.000
无	41(84)	50(85)
有	8(16)	9(15)

下载: 导出CSV

表 2 再出血的发生率

Table 2. Incidence of rebleeding

再出血时间	西医组 (n=49)	中西医组 (n=59)	P值
早期再出血[例(%)]
6周内	1(2)	1(2)	1.0
迟发性再出血[例(%)]
6周~6个月	3(6)	4(7)	1.0
7~12个月	2(4)	2(3)	1.0
13~24个月	6(12)	1(2)	0.045
25个月以后	0	1(2)	1.0

下载: 导出CSV

表 3 Cox回归分析

Table 3. Cox regression analysis

变量	B值	SE	Wald	Exp(B)	P值
组别	-0.037	0.554	0.004	0.964	0.947
性别	0.900	0.826	1.187	2.459	0.276
年龄	0.008	0.030	0.068	1.008	0.795
内镜治疗次数	-0.630	0.372	2.871	0.533	0.090
入组时食管静脉曲张分级	0.738	1.191	0.384	2.091	0.536
是否合并胃底静脉曲张	-1.198	0.898	1.779	0.302	0.182
是否合并PHG			0.367		0.832
轻度	0.184	0.738	0.062	1.202	0.803
重度	0.426	0.707	0.363	1.532	0.547
病程	0.093	0.081	1.343	1.098	0.247
基础疾病	1.546	0.655	5.572	4.693	0.018
饮酒史	0.892	0.847	1.109	2.440	0.292
吸烟史	0.977	0.805	1.475	2.657	0.225
肝硬化原因	0.674	0.700	0.926	1.962	0.336
肝功能Child-Pugh分级	1.550	0.539	8.260	4.713	0.004

下载: 导出CSV

参考文献(32)

[1]	ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
[2]	CHEN S, LI J, WANG D, et al. The hepatitis B epidemic in China should receive more attention[J]. Lancet, 2018, 391(10130): 1572. DOI: 10.1016/S0140-6736(18)30499-9.
[3]	de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[4]	XU XY, DING HG, JIA JD, et al. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002. 徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
[5]	LO GH, LAI KH, CHENG JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: A prospective, randomized trial[J]. Hepatology, 2000, 32(3): 461-465. DOI: 10.1053/jhep.2000.16236.
[6]	de LA PEÑA J, BRULLET E, SANCHEZ-HERNáNDEZ E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: A multicenter trial[J]. Hepatology, 2005, 41(3): 572-578. DOI: 10.1002/hep.20584.
[7]	ZHANG L. Clinical observation of hemostatic decoction combined tissue adhesive injection(TAI)on treatment of liver cirrhosis complicated by gastric venous bleeding[J]. Hubei J Tradit Chin Med, 2017, 39(11): 25-26. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ201711009.htm 张磊. 止血汤联合内镜下组织胶注射治疗肝硬化并发胃底静脉出血临床观察[J]. 湖北中医杂志, 2017, 39(11): 25-26. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ201711009.htm
[8]	NIU SS, ZHANG Q, HOU YX, et al. Primary preventive effect of anti-fibrosis treatment on esophageal and gastric varices bleeding in patients with cirrhosis: A real-world study[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006. 牛帅帅, 张群, 侯艺鑫, 等. 抗肝纤维化治疗对肝硬化食管胃静脉曲张出血的一级预防作用[J]. 中西医结合肝病杂志, 2019, 29(4): 305-309. DOI: 10.3969/j.issn.1005-0264.2019.04.006.
[9]	HOU YX, ZHANG Q, YANG ZY, et al. Effect of spleen-strengthening, dampness-removing, and hemostatic prescription on rebleeding within one year in cirrhotic patients with esophagogastric variceal bleeding[J]. J Clin Hepatol, 2018, 34(10): 2136-2141. DOI: 10.3969/j.issn.1001-5256.2018.10.015. 侯艺鑫, 张群, 杨志云, 等. 健脾化湿止血方对肝硬化食管胃底静脉曲张破裂出血患者1年内再出血的影响[J]. 临床肝胆病杂志, 2018, 34(10): 2136-2141. DOI: 10.3969/j.issn.1001-5256.2018.10.015.
[10]	XU XY, DING HG, LI WG, et al. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[11]	Esophageal and gastric varices group, Digestive Endoscopy Branch, Chinese Medical Association. Tentative guidelines for endoscopic diagnosis and treatment of varicosity and variceal bleeding in digestive tract (2009)[J]. China Contin Med Educ, 2010, 2(6): 21-26. DOI: 10.3969/j.issn.1674-9308.2010.06.003. 中华医学会消化内镜学分会食管胃静脉曲张学组. 消化道静脉曲张及出血的内镜诊断和治疗规范试行方案(2009年)[J]. 中国继续医学教育, 2010, 2(6): 21-26. DOI: 10.3969/j.issn.1674-9308.2010.06.003.
[12]	MC CORMACK TT, SIMS J, EYRE-BROOK I, et al. Gastric lesions in portal hypertension: Inflammatory gastritis or congestive gastropathy?[J]. Gut, 1985, 26(11): 1226-1232. DOI: 10.1136/gut.26.11.1226.
[13]	XU LM, LIU P, SHEN XZ, et al. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 徐列明, 刘平, 沈锡中, 等. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[14]	Digestive System Diseases Committee, Chinese Association of Integrative Medicine. Consensus on diagnosis and treatment of cirrhosis with integrated Traditional Chinese and Western medicine[J]. Chin J Integr Trad West Med Dig, 2011, 19(4): 277-279. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201104035.htm 中国中西医结合学会消化系统疾病专业委员会. 肝硬化中西医结合诊疗共识[J]. 中国中西医结合消化杂志, 2011, 19(4): 277-279. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201104035.htm
[15]	Study Group of Spleen and Portal Hypertension Surgery, Chinese Surgical Society, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension (2019 edition)[J]. Chin J Pract Surg, 2019, 39(12): 1241-1247. DOI: 10.19538/j.cjps.issn1005-2208.2019.12.01. 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(12): 1241-1247. DOI: 10.19538/j.cjps.issn1005-2208.2019.12.01.
[16]	LI Q, ZHOU X, XU KS. The clinical therapeutic effect of Rebamipide on portal hypertensive gastropathy[J]. Chin J Gastroenterol Hepatol, 2006, 15(3): 264-267. https://www.cnki.com.cn/Article/CJFDTOTAL-WCBX200603011.htm 李琪, 周霞, 徐可树. 瑞巴派特对门脉高压性胃病的临床疗效观察[J]. 胃肠病学和肝病学杂志, 2006, 15(3): 264-267. https://www.cnki.com.cn/Article/CJFDTOTAL-WCBX200603011.htm
[17]	GARCIA-TSAO G, BOSCH J. Varices and variceal hemorrhage in cirrhosis: A new view of an old problem[J]. Clin Gastroenterol Hepatol, 2015, 13(12): 2109-2117. DOI: 10.1016/j.cgh.2015.07.012.
[18]	VUACHET D, CERVONI J P, VUITTON L, et al. Improved survival of cirrhotic patients with variceal bleeding over the decade 2000-2010[J]. Clin Res Hepatol Gastroenterol, 2015, 39(1): 59-67. DOI: 10.1016/j.clinre.2014.06.018.
[19]	WILLIAMS R, ASPINALL R, BELLIS M, et al. Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis[J]. Lancet, 2014, 384(9958): 1953-1997. DOI: 10.1016/S0140-6736(14)61838-9.
[20]	BOSCH J, SAUERBRUCH T. Esophageal varices: Stage-dependent treatment algorithm[J]. J Hepatol, 2016, 64(3): 746-748. DOI: 10.1016/j.jhep.2015.11.039.
[21]	LIU P, HU YY, LIU C, et al. Multi-centrally clinical trial of Fuzhenghuayu (Strengthening Healthy Qi to Solve Stagnation) capsules on liver filbrosis caused by chronic hepatitis B[J]. World Sci Technol Modern Tradit Chin Med, 2005, 7(1): 24-32. DOI: 10.3969/j.issn.1674-3849.2005.01.006. 刘平, 胡义扬, 刘成, 等. 扶正化瘀胶囊干预慢性乙型肝炎肝纤维化作用的多中心临床观察[J]. 世界科学技术-中医药现代化, 2005, 7(1): 24-32. DOI: 10.3969/j.issn.1674-3849.2005.01.006.
[22]	XIAO DH, GU J, CAI H, et al. A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis[J]. Chin J Hepatol, 2014, 22(8): 594-599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009. 肖定洪, 顾杰, 蔡虹, 等. 扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J]. 中华肝脏病杂志, 2014, 22(8): 594-599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009.
[23]	LIU XD, HUI LM, WANG JH, et al. The clinical effect of endoscopic ligation combined with traditional Chinese and Western medicines on liver cirrhosis esophagogastric variceal bleeding[J]. Chin J Integr Trad West Med Dig, 2019, 27(6): 436-440. DOI: 10.3969/j.issn.1671-038X.2019.06.08. 刘晓东, 回丽妹, 王建华, 等. 内镜套扎联合中西药治疗肝硬化食管静脉曲张破裂出血的临床研究[J]. 中国中西医结合消化杂志, 2019, 27(6): 436-440. DOI: 10.3969/j.issn.1671-038X.2019.06.08.
[24]	YUAN C, HAO JM, WU WP, et al. Clinical study on Prevention of Recent Rebleeding after ligation of esophageal varices with cirrhosis by Yang Zhen's "Heweifugan Decoction"[C]//2019 The fourth Academic Exchange meeting of the first Digestive Endoscopy Professional Committee of Chinese Society of Integrated Traditional and Western Medicine. 2019: 24. DOI: 10.26914/c.cnkihy.2019.001223. 袁超, 郝建梅, 吴文平, 等. 杨震"和胃复肝汤"预防肝硬化食管静脉曲张套扎术后近期再出血的临床研究[C]//2019中国中西医结合学会消化内镜学专业委员会第一届第四次学术交流会摘要集. 2019: 24. DOI: 10.26914/c.cnkihy.2019.001223.
[25]	LIU HL, YAN S, LIU Y, et al. Efficacy and safety of carvedilol plus endoscopic variceal ligation for secondly prophylaxis of variceal bleeding in cirrhotic patients[J]. China J Endosc, 2015, 21(2): 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGNJ201502005.htm 刘浩雷, 燕晟, 刘瑛, 等. 卡维地洛联合内镜套扎术预防食管静脉曲张再次出血的疗效及安全性分析[J]. 中国内镜杂志, 2015, 21(2): 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGNJ201502005.htm
[26]	YANG J, GE K, CHEN L, et al. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: A meta-analysis[J]. Eur J Gastroenterol Hepatol, 2019, 31(12): 1518-1526. DOI: 10.1097/MEG.0000000000001442.
[27]	LIU B, FANG ZY, MENG DM, et al. Progress of prevention and treatment of complications of liver cirrhosis[J]. J Chin Pract Diagn Ther, 2016, 30(12): 1152-1155. DOI: 10.13507/j.issn.1674-3474.2016.12.003. 刘斌, 方正亚, 孟冬梅, 等. 肝硬化并发症治疗及预防研究进展[J]. 中华实用诊断与治疗杂志, 2016, 30(12): 1152-1155. DOI: 10.13507/j.issn.1674-3474.2016.12.003.
[28]	SHI ZH, RUAN JJ, HU SP. Clinical observation on 40 cases of portal hypertension gastropathy treated with combined Chinese Drugs[J]. JTCM, 2001, 42(6): 353-354. DOI: 10.3321/j.issn:1001-1668.2001.06.020. 时昭红, 阮景军, 胡少鹏. 中药配合治疗门脉高压性胃病40例临床观察[J]. 中医杂志, 2001, 42(6): 353-354. DOI: 10.3321/j.issn:1001-1668.2001.06.020
[29]	WANG YH, DUAN SS. Effects of weikang mixture on portal hypertensive gastropathy after esophageal varice ligation[J]. J Hunan Univ Chin Med, 2017, 37(9): 982-985. DOI: 10.3969/j.issn.1674-070X.2017.09.016. 王永恒, 段姗姗. 胃康合剂对食管静脉曲张套扎术后门脉高压性胃病的影响[J]. 湖南中医药大学学报, 2017, 37(9): 982-985. DOI: 10.3969/j.issn.1674-070X.2017.09.016.
[30]	WEI G, BEI GM, LI HQ. Clinical research of yao minority medical plaster on patients with portal hypertensive gastropathy of deficiency cold of spleen and stomach pattern[J]. World Chin Med, 2016, 11(9): 1807-1810. DOI: 10.3969/j.issn.1673-7202.2016.09.042. 韦刚, 贝光明, 李海强. 瑶医膏药治疗脾胃虚寒型门脉高压性胃病的临床观察[J]. 世界中医药, 2016, 11(9): 1807-1810. DOI: 10.3969/j.issn.1673-7202.2016.09.042.
[31]	ALBILLOS A, ZAMORA J, J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis[J]. Hepatology, 2017, 66(4): 1219-1231. DOI: 10.1002/hep.29267.
[32]	ZHANG SY, HUANG HC, WANG XM. Factors influencing prognosis for cirrhotic patients with esophagogastric variceal bleeding within 1 year after endoscopic variceal ligation[J]. Chin Hepatol, 2021, 26(2): 155-158. DOI: 10.3969/j.issn.1008-1704.2021.02.016. 张生燕, 黄宏春, 王秀敏. 肝硬化食管胃底静脉曲张出血内镜套扎术后1年预后的影响因素观察[J]. 肝脏, 2021, 26(2): 155-158. DOI: 10.3969/j.issn.1008-1704.2021.02.016.